Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa; National Institute for Health Research Health Protection Research Unit in Healthcare-Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK; Department of Health Sciences Research, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India; ESCMID Study Group for Antimicrobial Stewardship, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Lancet Glob Health. 2023 Mar;11(3):e466-e474. doi: 10.1016/S2214-109X(23)00019-0. Epub 2023 Feb 2.
At the 2015 World Health Assembly, UN member states adopted a resolution that committed to the development of national action plans (NAPs) for antimicrobial resistance (AMR). The political determination to commit to NAPs and the availability of robust governance structures to assure sustainable translation of the identified NAP objectives from policy to practice remain major barriers to progress. Inter-country variability in economic and political resilience and resource constraints could be fundamental barriers to progressing AMR NAPs. Although there have been regional and global analyses of NAPs from a One Health and policy perspective, a global assessment of the NAP objectives targeting antimicrobial use in human populations is needed. In this Health Policy, we report a systematic evidence synthesis of existing NAPs that are aimed at tackling AMR in human populations. We find marked gaps and variability in maturity of NAP development and operationalisation across the domains of: (1) policy and strategic planning; (2) medicines management and prescribing systems; (3) technology for optimised antimicrobial prescribing; (4) context, culture, and behaviours; (5) operational delivery and monitoring; and (6) patient and public engagement and involvement. The gaps identified in these domains highlight opportunities to facilitate sustainable delivery and operationalisation of NAPs. The findings from this analysis can be used at country, regional, and global levels to identify AMR-related priorities that are relevant to infrastructure needs and contexts.
在 2015 年世界卫生大会上,联合国会员国通过了一项决议,承诺制定国家行动计划(NAP)以应对抗微生物药物耐药性(AMR)。承诺制定国家行动计划以及建立健全的治理结构,以确保将确定的国家行动计划目标从政策转化为实践,这仍然是进展的主要障碍。国家间经济和政治弹性以及资源限制方面的差异可能是推进 AMR 国家行动计划的根本障碍。尽管从“同一健康”和政策角度对国家行动计划进行了区域和全球分析,但仍需要对针对人口中抗菌药物使用的国家行动计划目标进行全球评估。在本卫生政策中,我们报告了对旨在解决人口中 AMR 问题的现有国家行动计划的系统证据综合分析。我们发现,在以下领域,国家行动计划的制定和运作的成熟度存在明显差距和差异:(1)政策和战略规划;(2)药品管理和处方系统;(3)优化抗菌药物处方的技术;(4)背景、文化和行为;(5)运营交付和监测;以及(6)患者和公众的参与和投入。这些领域中发现的差距突出了促进国家行动计划可持续交付和运作的机会。该分析的结果可用于国家、区域和全球各级,以确定与基础设施需求和背景相关的与 AMR 相关的优先事项。